Garuda Wins Big: Revolutionizing Stem Cell Therapy
Garuda Therapeutics has been honored with the prestigious title of “Overall Cell Biology Company of the Year” by BioTech Breakthrough, an independent organization that recognizes top performers in the life sciences and biotechnology sectors. This accolade was awarded to Garuda for their innovative approach to creating off-the-shelf hematopoietic stem cell (HSC) therapies. These therapies are […]
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD33 and CLL-1 in human hematopoietic stem cells (HSCs) demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia (AML). The data […]